98%
921
2 minutes
20
Introduction And Objectives: The association of low-density lipoprotein cholesterol (LDL-C) levels and prognosis in patients with heart failure (HF) remains uncertain. This study aimed to evaluate the prognostic significance of LDL-C in patients admitted for acutely decompensated HF and establish a safety cut-off value in this population.
Methods: This retrospective, observational study included 167 consecutive patients admitted for acute HF. LDL-C levels were measured on hospital admission, and patients were categorized according to their estimated cardiovascular (CV) risk. The primary endpoint was all-cause mortality at one-year, while secondary endpoints included HF hospitalizations, major thrombotic events, and net clinical benefit.
Results: During the follow-up period, 14.4% of patients died. Higher LDL-C levels were independently associated with improved survival, with a 4-fold increase in survival probability for each 1 mg/dL increase in serum LDL-C. The minimum LDL-C value not associated with increased mortality risk was 88 mg/dL. Patients with LDL-C below this cut-off had a significantly higher risk of mortality and a tendency for higher HF hospitalization risk. The net clinical benefit endpoint was also influenced by LDL-C levels, with LDL-C below 88 mg/dL associated with an increased risk of events.
Conclusion: In patients admitted for acutely decompensated HF, higher LDL-C levels were associated with reduced risk of mortality. An LDL-C value below 88 mg/dL was associated with increased mortality, suggesting the need for a more liberal LDL-C target in this specific patient population. These findings highlight the importance of considering LDL-C levels in the management and risk assessment of patients with HF.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.repc.2024.09.004 | DOI Listing |
Eur Heart J Qual Care Clin Outcomes
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Background And Aims: Additional epidemiologic evidence is warranted regarding the appropriate timing of statin initiation for incidentally found dyslipidemia in general health check-ups. This study examined the association between the statin initiation timing and the risk of myocardial infarction (MI) in individuals with incidentally detected high low-density-lipoprotein cholesterol (LDL-C).
Methods: Participants aged 20 years or older who underwent annual health checkups from 2009 to 2012 were included.
J Cardiovasc Transl Res
September 2025
School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519000, China.
Atherosclerosis remains a leading cause of cardiovascular disease and mortality worldwide, despite advancements in statin therapies. Here, we aimed to identify potential anti-atherosclerosis drugs by an integrated approach combining network medicine-based prediction with empirical validation. Among the top drugs predicted by the preferred algorithm, mesalazine─a drug traditionally used to treat inflammatory bowel disease, was selected for in vivo validation in ApoE mouse model of atherosclerosis.
View Article and Find Full Text PDFAm Heart J Plus
October 2025
Department of Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Introduction: Cigarette smoking is a well-recognized independent risk factor for numerous cardiovascular disorders and contributes to the increasing morbidity and mortality associated with chronic heart diseases (CHD). This study aimed to evaluate how cigarette smoking affects lipid metabolism and inflammatory processes, along with other related mechanisms, in order to better understand the potential cardiovascular risks faced by smokers.
Objectives: To evaluate and compare the serum lipid profile and high-sensitivity C-reactive protein levels between cigarette smokers and non-smokers.
Front Genet
August 2025
Federal Medical and Biologicl Agency, Moscow, Russia.
Background: Familial hypercholesterolemia (FH) is a prevalent hereditary disorder, with its monogenic form linked to an elevated risk of early-onset ischemic heart disease. Evaluating the prevalence and penetrance of pathogenic and likely pathogenic variants associated with this disorder would provide valuable information supporting routine FH screening of the general population. Such informed screening would facilitate early identification of at-risk individuals, enabling timely intervention and management.
View Article and Find Full Text PDFJ Clin Invest
September 2025
Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, United States of America.
Background: Statin therapy lowers the risk of major adverse cardiovascular events (MACE) among people with HIV (PWH). Residual risk pathways contributing to excess MACE beyond low-density lipoprotein cholesterol (LDL-C) are not well understood. Our objective was to evaluate the association of statin responsive and other inflammatory and metabolic pathways to MACE in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).
View Article and Find Full Text PDF